Head and Neck Cancer Drugs Market To Reach $2.58 Billion By 2029 says Visiongain report

20 December 2019
Pharma

Visiongain’s new report the Head and Neck Cancer Drugs Market Report 2019-2029: Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug stores & retail pharmacies), plus analysis of leading companies operating in the global head and neck cancer drugs market.

Increasing global geriatric population, growing prevalence of neck and head cancer, and increasing tobacco and alcohol consumption is expected to increase global head and neck cancer drugs market over the projected period. In 2019, the global head and neck cancer drugs market was valued at $963 million and is expected to reach $2.58 billion by 2029 at a CAGR of 10.3% over the projected period.

According to the World Health Organization, tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Tobacco consumption is ranked as the leading cause of illness, death, and impoverishment. Increasing tobacco consumption has increased the prevalence of head and neck cancer over the past few years and the trend is expected to continue over the course of time. 

Increasing geriatric population in developed as well as developing economies are expected to prone more towards chronic diseases, which in turn is expected to drive the head and neck cancer drugs market. Some identified disruptive drugs are Opdivo, Keytruda, Imfinzi, Bavencio, Yervoy, Tremelimumab, Buparlisib, and Epacadostat.

List of head and neck cancer drugs providers identified in this report are  Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever